79.30
price down icon0.81%   -0.66
 
loading
전일 마감가:
$79.96
열려 있는:
$80.155
하루 거래량:
7.45M
Relative Volume:
0.49
시가총액:
$199.23B
수익:
$63.92B
순이익/손실:
$17.43B
주가수익비율:
11.54
EPS:
6.87
순현금흐름:
$17.04B
1주 성능:
-5.21%
1개월 성능:
+0.32%
6개월 성능:
-17.59%
1년 성능:
-36.94%
1일 변동 폭
Value
$78.95
$80.31
1주일 범위
Value
$78.95
$84.36
52주 변동 폭
Value
$73.31
$128.73

머크앤드컴퍼니 Stock (MRK) Company Profile

Name
명칭
Merck Co Inc
Name
전화
908-740-4000
Name
주소
126 EAST LINCOLN AVENUE, RAHWAY, NJ
Name
직원
75,000
Name
트위터
@Merck
Name
다음 수익 날짜
2025-02-04
Name
최신 SEC 제출 서류
Name
MRK's Discussions on Twitter

MRK을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - General icon
MRK
Merck Co Inc
79.34 210.10B 63.92B 17.43B 17.04B 6.87
Drug Manufacturers - General icon
LLY
Lilly Eli Co
761.90 717.60B 49.00B 11.11B -1.27B 12.29
Drug Manufacturers - General icon
JNJ
Johnson Johnson
164.20 377.32B 90.63B 22.66B 18.57B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
185.15 338.30B 57.37B 4.20B 15.39B 2.35
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
114.34 234.32B 55.19B 13.65B 16.81B 6.86
Drug Manufacturers - General icon
NVO
Novo Nordisk Adr
64.76 306.33B 43.59B 15.04B 10.74B 3.3766

머크앤드컴퍼니 Stock (MRK) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-05-14 다운그레이드 Citigroup Buy → Neutral
2025-04-22 개시 Cantor Fitzgerald Neutral
2025-02-18 다운그레이드 Deutsche Bank Buy → Hold
2025-02-10 다운그레이드 TD Cowen Buy → Hold
2025-01-08 다운그레이드 Truist Buy → Hold
2024-12-20 다운그레이드 BMO Capital Markets Outperform → Market Perform
2024-12-10 재개 BofA Securities Buy
2024-12-04 업그레이드 HSBC Securities Hold → Buy
2024-11-15 개시 Wolfe Research Peer Perform
2024-11-11 다운그레이드 Daiwa Securities Buy → Neutral
2024-10-17 개시 Bernstein Mkt Perform
2024-03-11 다운그레이드 Societe Generale Hold → Sell
2024-01-04 업그레이드 TD Cowen Market Perform → Outperform
2023-11-09 개시 Deutsche Bank Buy
2023-10-27 업그레이드 BMO Capital Markets Market Perform → Outperform
2023-10-20 업그레이드 UBS Neutral → Buy
2023-07-14 개시 HSBC Securities Hold
2023-04-13 업그레이드 Citigroup Neutral → Buy
2023-03-28 다운그레이드 Societe Generale Buy → Hold
2023-03-13 다운그레이드 Wells Fargo Overweight → Equal Weight
2023-03-06 개시 Jefferies Buy
2023-02-22 업그레이드 Wolfe Research Peer Perform → Outperform
2023-01-04 업그레이드 BofA Securities Neutral → Buy
2022-11-18 개시 Credit Suisse Outperform
2022-10-10 업그레이드 Guggenheim Neutral → Buy
2022-09-14 업그레이드 Berenberg Hold → Buy
2022-07-06 업그레이드 Daiwa Securities Neutral → Buy
2022-06-06 재개 SVB Leerink Outperform
2022-04-06 재개 Morgan Stanley Equal-Weight
2021-12-17 개시 Goldman Buy
2021-12-16 개시 Daiwa Securities Neutral
2021-12-13 다운그레이드 UBS Buy → Neutral
2021-12-09 개시 Wells Fargo Overweight
2021-12-07 다운그레이드 Guggenheim Buy → Neutral
2021-11-29 다운그레이드 Citigroup Buy → Neutral
2021-11-19 개시 BMO Capital Markets Market Perform
2021-11-01 업그레이드 Argus Hold → Buy
2021-09-07 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2021-07-27 재개 Truist Buy
2021-05-20 다운그레이드 Argus Buy → Hold
2021-04-07 재개 RBC Capital Mkts Sector Perform
2020-11-10 재개 Bernstein Outperform
2020-09-29 개시 Berenberg Hold
2020-08-03 업그레이드 Goldman Neutral → Buy
2020-06-12 다운그레이드 Wolfe Research Outperform → Peer Perform
2020-02-27 개시 Barclays Overweight
2020-01-07 개시 RBC Capital Mkts Sector Perform
2019-10-17 재개 BofA/Merrill Neutral
2019-08-16 개시 SVB Leerink Outperform
2019-07-03 개시 Mizuho Buy
2019-05-28 개시 Goldman Neutral
2019-05-13 업그레이드 Atlantic Equities Neutral → Overweight
2018-10-16 재확인 Citigroup Buy
2018-10-09 재개 Guggenheim Buy
2018-04-23 업그레이드 Goldman Neutral → Buy
2018-04-17 업그레이드 Morgan Stanley Equal-Weight → Overweight
2018-04-05 업그레이드 Barclays Equal Weight → Overweight
2018-03-12 업그레이드 Leerink Partners Mkt Perform → Outperform
2018-02-14 재확인 Leerink Partners Mkt Perform
2018-02-07 재확인 Morgan Stanley Equal-Weight
2018-01-16 업그레이드 SunTrust Hold → Buy
모두보기

머크앤드컴퍼니 주식(MRK)의 최신 뉴스

pulisher
10:00 AM

Merck Commits to Veeva Vault CRM – Company Announcement - Financial Times

10:00 AM
pulisher
Jul 20, 2025

Should You Forget Pfizer and Buy This Magnificent Dividend Stock Instead? - The Motley Fool

Jul 20, 2025
pulisher
Jul 19, 2025

MERCK ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire

Jul 19, 2025
pulisher
Jul 18, 2025

Peter Lynch's Investment Strategy: A Detailed Analysis of MERCK & CO INC (MRK) - AInvest

Jul 18, 2025
pulisher
Jul 18, 2025

Merck’s (MRK) Dividend History: A Track Record of Consistency - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

Jefferies Raises Merck (MRK) Price Target, Maintains Buy Rating - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

Merck KGaA gets EU nod for Ezmekly (MRK:NYSE) - Seeking Alpha

Jul 18, 2025
pulisher
Jul 18, 2025

Livestock Identification Company Evaluation Report 2025 | Merck, Shearwell, Datamars Drive Innovations with Comprehensive Tagging and Tracking Solutions - Yahoo Finance

Jul 18, 2025
pulisher
Jul 18, 2025

Morgan Stanley Lowered the Firm’s PT on Merck & Co (MRK), Kept a Hold Rating - Insider Monkey

Jul 18, 2025
pulisher
Jul 18, 2025

Merck’s SWOT analysis: stock faces keytruda patent cliff, gardasil challenges - Investing.com

Jul 18, 2025
pulisher
Jul 18, 2025

Merck’s SWOT analysis: stock faces keytruda patent cliff, gardasil challenges By Investing.com - Investing.com UK

Jul 18, 2025
pulisher
Jul 16, 2025

Why Merck Is A Better Dividend Stock Than Gilead Sciences (NYSE:MRK) - Seeking Alpha

Jul 16, 2025
pulisher
Jul 15, 2025

Merck & Co., Inc. (MRK) Is Unlikely To Face Antitrust Action For Verona Deal, Says Jim Cramer - Insider Monkey

Jul 15, 2025
pulisher
Jul 15, 2025

Merck Starts Phase III Studies on Once-Monthly Pill for HIV Prevention - Yahoo Finance

Jul 15, 2025
pulisher
Jul 14, 2025

The Zacks Analyst Blog Highlights Microsoft, Alibaba Group, Merck, Monarch Cement and Team - Yahoo Finance

Jul 14, 2025
pulisher
Jul 14, 2025

Merck & Co advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Merck to Start Phase 3 Trials of MK-8527 for HIV Prevention - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill - Business Wire

Jul 14, 2025
pulisher
Jul 13, 2025

Verona Pharma (VRNA) Opinions on Merck Acquisition News - Quiver Quantitative

Jul 13, 2025
pulisher
Jul 12, 2025

Merck & Co., Inc. (MRK)’s CEO Thinks He’s Got $50 Billion Of New Drugs, Says Jim Cramer - MSN

Jul 12, 2025
pulisher
Jul 12, 2025

UBS Affirms Merck & Co’s (MRK) ‘Buy’ Rating on HPV Vaccine Prospects - MSN

Jul 12, 2025
pulisher
Jul 12, 2025

Key deals this week: Meta, Boyd Gaming, Merck, Sandstorm Gold, Capgemini and more - Seeking Alpha

Jul 12, 2025
pulisher
Jul 12, 2025

Verona Pharma plc (VRNA): Jim Cramer Approves The Merck Acquisition - Yahoo Finance

Jul 12, 2025
pulisher
Jul 11, 2025

Success Tricking FDA Shouldn't Protect Merck, Justices Told - Law360

Jul 11, 2025
pulisher
Jul 11, 2025

Merck to Acquire Verona Pharma in $10B Bid - USA Herald

Jul 11, 2025
pulisher
Jul 11, 2025

Top Analyst Reports for Microsoft, Alibaba & Merck - TradingView

Jul 11, 2025
pulisher
Jul 11, 2025

FDA Accepts Merck's Filing for Two-Drug, Once-Daily HIV Pill - Yahoo Finance

Jul 11, 2025
pulisher
Jul 11, 2025

With Verona deal, Merck wagers on strength of lung drug’s patents - BioPharma Dive

Jul 11, 2025
pulisher
Jul 11, 2025

Merck: Jefferies raises TP after Verona acquisition - MarketScreener

Jul 11, 2025
pulisher
Jul 11, 2025

Jefferies Adjusts Merck & Co.'s Price Target to $141 From $138, Keeps Buy Rating - MarketScreener

Jul 11, 2025
pulisher
Jul 11, 2025

Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock? - Nasdaq

Jul 11, 2025
pulisher
Jul 10, 2025

Merck Animal Health gets FDA nod for Bravecto Quantum (MRK:NYSE) - Seeking Alpha

Jul 10, 2025
pulisher
Jul 10, 2025

Merck Animal Health's Flea-and-Tick Treatment Approved in U.S. - MarketScreener

Jul 10, 2025
pulisher
Jul 10, 2025

QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health - Business Wire

Jul 10, 2025
pulisher
Jul 10, 2025

Merck & Co. Remains In The BD Game After Verona Takeout - insights.citeline.com

Jul 10, 2025
pulisher
Jul 10, 2025

Merck Acquires Verona Pharma for $10B to Support Portfolio with COPD Drug Ohtuvayre Ahead of Keytruda Patent Expiration - Insider Monkey

Jul 10, 2025
pulisher
Jul 10, 2025

Merck's doravirine/islatravir under FDA review for HIV (MRK:NYSE) - Seeking Alpha

Jul 10, 2025
pulisher
Jul 10, 2025

U.S. FDA Accepts New Drug Application for Merck’s Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection - Business Wire

Jul 10, 2025
pulisher
Jul 10, 2025

Merck to acquire UK drugmaker Verona Pharma for $10bn - World Pharmaceutical Frontiers

Jul 10, 2025
pulisher
Jul 10, 2025

Foley Represents Verona Pharma in $10B Acquisition by Merck - Foley & Lardner LLP

Jul 10, 2025
pulisher
Jul 09, 2025

Merck (MRK) Rises Higher Than Market: Key Facts - Yahoo Finance

Jul 09, 2025
pulisher
Jul 09, 2025

Merck & Co.’s Verona Acquisition Marks A Return To Respiratory - insights.citeline.com

Jul 09, 2025
pulisher
Jul 09, 2025

In a $10B deal, Merck buys cardio developer Verona - BioWorld MedTech

Jul 09, 2025
pulisher
Jul 09, 2025

Merck spends $10 billion for Verona, gaining access to its COPD medication - Jacksonville Journal-Courier

Jul 09, 2025
pulisher
Jul 09, 2025

Merck Buys Verona Pharma: A Good Deal, But M&A Spree Must Continue (NYSE:MRK) - Seeking Alpha

Jul 09, 2025
pulisher
Jul 09, 2025

Merck to buy Verona and its lung drug in $10B deal - BioPharma Dive

Jul 09, 2025
pulisher
Jul 09, 2025

Merck to Buy Verona Pharma in $10 Billion Deal - The Wall Street Journal

Jul 09, 2025
pulisher
Jul 09, 2025

Merck to acquire Verona Pharma for $10 billion - Reuters

Jul 09, 2025
pulisher
Jul 09, 2025

Verona Pharma Stock Jumps 20%. It’s Being Bought for $10 Billion by Merck. - Barron's

Jul 09, 2025
pulisher
Jul 09, 2025

Verona Pharma Stock Soars to All-Time High as Merck Buys Firm for $10B - Investopedia

Jul 09, 2025
pulisher
Jul 09, 2025

Freshfields Guides Merck's $10B Deal For Verona Pharma - Law360

Jul 09, 2025

머크앤드컴퍼니 (MRK) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
drug_manufacturers_general NVO
$64.78
price up icon 0.75%
$295.04
price up icon 0.11%
drug_manufacturers_general NVS
$115.08
price up icon 0.71%
drug_manufacturers_general PFE
$24.53
price up icon 0.08%
$108.25
price down icon 0.40%
자본화:     |  볼륨(24시간):